Titre :

Epidemiology of myasthenia gravis in France: A retrospective claims database study (STAMINA).

Auteur(s) :

Salort-Campana, E. [Auteur]
Laforet, P. [Auteur]
De Pouvourville, G. [Auteur]
Crochard, A. [Auteur]
UCB Pharma, Colombes
Chollet, G. [Auteur]
Nevoret, C. [Auteur]
Emery, C. [Auteur]
Bouée, S. [Auteur]
Tard, Celine [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172

Titre de la revue :

Revue Neurologique

Nom court de la revue :

Rev Neurol (Paris)

Numéro :

180

Pagination :

202-210

Éditeur :

Elsevier

Date de publication :

2023-11-18

ISSN :

0035-3787

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Background The objectives of this observational study were to report the incidence and prevalence of myasthenia gravis (MG) in France, describe patients’ characteristics and treatment patterns, and estimate mortality. Methods A ...
Lire la suite >Background The objectives of this observational study were to report the incidence and prevalence of myasthenia gravis (MG) in France, describe patients’ characteristics and treatment patterns, and estimate mortality. Methods A historical cohort analysis was performed using the French National Health Data System (SNDS) database between 2008 and 2020. Patients with MG were identified based on ICD-10 codes during hospitalization and/or long-term disease (ALD) status, which leads to a 100% reimbursement for healthcare expenses related to MG. The study population was matched to a control group based on age, sex and region of residence. Results The overall incidence of MG was estimated at 2.5/100,000 in 2019 and the overall prevalence at 34.2/100,000. The mean age was 58.3 years for incident patients and 58.6 for prevalent patients. Among patients with MG, 57.1% were women. In the first year after identification of MG, acetylcholinesterase inhibitors were the most commonly used treatments (87.0%). Corticosteroids were delivered to 58.3% of patients, intravenous immunoglobulin to 34.4%, and azathioprine to 29.9%. Additionally, 8% of patients underwent thymectomy. The proportions of patients with exacerbations and crises were 59.7% and 13.5% respectively in the first year after MG identification. All-cause mortality was significantly higher in patients with MG compared to matched controls (HR = 1.82 (95% CI [1.74;1.90], P < 0.0001)). Conclusion In this study, the incidence and prevalence of MG estimated in France were found to be higher than previously reported. Most exacerbations and crises occurred within the first year after MG identification. MG was associated with increased mortality compared to a control population matched on age, gender, and geographical region.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172

Date de dépôt :

2024-01-15T22:09:45Z
2024-10-16T07:33:32Z